Cytosorbents Corp (CTS) 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Cytosorbents Corporation on July 11, 2023, covering events occurring on July 7, 2023. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements, specifically the approval of incentive equity awards for named executive officers by the Board of Directors and the Compensation Committee.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation details.
Material Changes and Compensation Details
On July 7, 2023, the Company approved the following equity awards for its named executive officers. Base salaries for 2023 remained unchanged from 2022 levels.
| Executive Officer | Position | Annual Incentive Stock Options | Restricted Stock Units (RSUs) | One-Time Catch-Up Stock Options |
|---|---|---|---|---|
| Phillip P. Chan, MD, PhD | Chief Executive Officer | 112,000 | 87,000 | 48,000 |
| Vincent J. Capponi | President and COO | 91,000 | 73,000 | 42,000 |
| Efthymios N. Deliargyris, MD | Chief Medical Officer | 78,000 | 55,000 | 40,000 |
Additionally, Interim Chief Financial Officer Kathleen Bloch received 20,000 options vesting in full on the first anniversary.
Terms and Conditions:
- Strike Price: $3.53 per share (closing price on July 7, 2023).
- Term: 10 years for stock options.
- Vesting Schedules:
- Annual ISOs: 50% at year 1, 25% at year 2, 25% at year 3.
- Annual RSUs: 66.7% at year 1, 33.3% at year 2.
- Catch-Up ISOs: 50% at year 1, 50% at year 2.
- Purpose: Annual awards recognize 2022 performance; Catch-Up awards compensate for salary freezes over the preceding two years and recent inflation.
Guidance, Risks, and Contingencies
Contingent Settlement Risk: All equity awards described are granted on a contingent basis. They are subject to cash settlement unless the Company receives shareholder approval to amend its 2014 Long-Term Incentive Plan to increase the number of shares available for issuance. This amendment must be sufficient to permit non-cash settlement of these awards prior to the settlement date.
The filing does not contain forward-looking guidance, management commentary on financial outlook, or other risk factors beyond the contingent nature of the equity awards.
Investor Verification Checklist
- Verify the status of the shareholder vote required to amend the 2014 Long-Term Incentive Plan to allow non-cash settlement of the contingent awards.
- Confirm the total number of shares currently available under the 2014 Long-Term Incentive Plan to assess the likelihood of the amendment passing.
- Review the Company's cash position to understand the potential cash outflow if the awards are settled in cash due to a lack of share availability.
- Monitor future filings for updates on the vesting status and settlement method of these specific awards.